IN YOUR WORLD, EXPERIENCE MATTERS

Hemophilia with Inhibitors

BOB has hemophilia A with inhibitors.

For people with hemophilia A or B with inhibitors:
- Administer as a slow bolus injection over 2-5 minutes, depending on the dose administered.

Compassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

Please see additional Important Safety Information throughout.

Please see accompanying Prescribing Information.

Controlling bleeds, whenever they happen
- Proven to treat bleeds for people with hemophilia A or B with inhibitors
- Safety supported by clinical experience
  - 0.2% rate of blood clots reported in clinical trials

Speed when it's needed
- Fast to mix, fast to infuse, and fast to control bleeds

NovoSeven® RT—committed to your experience
- More than 30 years of research and long-term clinical experience

AFTER 30 YEARS
STILL RECOMBINANT
CONTROLLING BLEEDS
RAPID TO USE

Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:
- Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
- Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
- Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

Learn more at NovoSevenRT.com

CHASE has hemophilia A with inhibitors.

NovoSeven® RT:
Experience where it matters

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

FEIBA® is a registered trademark of Baxalta Incorporated.

© 2019 Novo Nordisk   Printed in the U.S.A.

US18NSVN00084   January 2019

13

Experience fast bleed control with NovoSeven® RT

NovoSeven® RT
90 mcg/kg
2-5 minutes

FEIBA
75 U/kg
37.5 minutes

d

• NovoSeven® RT can be redosed every 2 hours, which lets you dose as needed to get bleeds under control fast
• Your hemophilia treatment center (HTC) and your doctor will help you decide which dosing schedule is best for you

Fast to infuse
When bleeds happen, stopping them quickly is important. The faster you infuse treatment, the sooner it can start working.
- NovoSeven® RT is given as an intravenous (IV) bolus injection
- NovoSeven® RT has 16x less infusion volume than FEIBA,
- NovoSeven® RT is up to 18x faster to infuse than FEIBA.

a,b,c,d Individual doses for a joint bleed are compared and based on an 88 kg (194 lb) person.

Patients are cautioned that the maximum injection or infusion rate must not exceed 2 units per kilogram of body weight.
Understanding hemophilia with inhibitors

Hemophilia is a bleeding disorder that prevents blood from clotting properly. People with hemophilia are missing or have less of a particular clotting factor in their bodies. As a result, they may need replacement clotting factor to help their blood clot. Patients with hemophilia A need factor VIII, and patients with hemophilia B need factor IX.

Sometimes, the body thinks that the replacement clotting factor used to control bleeds is foreign or harmful. In response, the body may develop antibodies, known as “inhibitors.” These inhibitors attack the clotting factor treatment and prevent it from working properly.

People who develop inhibitors need a different type of treatment to control bleeds
Bleeds happen. Treat early to reduce the damage

People who develop inhibitors can treat prophylactically (on a regular schedule), or on-demand (after a bleed happens). Even while taking prophylactic (regular) treatment, bleeds can still happen.

It is recommended that a bleed be treated within 2 hours; however, a review of data on people with hemophilia suggests

Delay in treatment of bleeds can cause issues such as
• Joint inflammation (pain, redness, and swelling)
• Cartilage damage (harm to the connective tissue between joints)
• Destruction of the joint (due to ongoing, long-term damage)

It’s important to have an on-demand treatment with you to stop bleeds whenever they happen
NovoSeven® RT:
Experience where it matters

Controlling bleeds, whenever they happen
• Proven to treat bleeds for people with hemophilia A or B with inhibitors

Safety supported by clinical experience
• 0.2% rate of blood clots reported in clinical trials

Speed when it’s needed
• Fast to mix, fast to infuse, and fast to control bleeds

NovoSeven® RT—committed to your experience
• More than 30 years of research and long-term clinical experience

What is NovoSeven® RT?
NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:
• Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions
• Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information
What is the most important information I should know about NovoSeven® RT?
NovoSeven® RT may cause serious side effects, including:
• Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
• Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
• Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

For people with hemophilia A or B with inhibitors.
`Administer as a slow bolus injection over 2-5 minutes, depending on the dose administered.
`Compassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.
Experience proven bleed control with NovoSeven® RT

- Efficacy seen in one of the largest trials studying hemophilia with inhibitors
  - Joint, target joint, skin, and mucous membrane, muscle, and other bleeding episodes (n=227 bleeding episodes)

**Important Safety Information**
What is the most important information I should know about NovoSeven® RT? (cont’d)

NovoSeven® RT may cause serious side effects, including: (cont’d)
- You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

Please see additional Important Safety Information throughout. Please see accompanying Prescribing Information.
NovoSeven® RT: Established safety profile that comes from experience\(^a\)

\(^a\) Compassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

The safety of NovoSeven® RT is well studied

- Works at the site of injury
- A low rate of blood clots (0.2%) has been reported in clinical trials\(^b\)

\(^b\) For people with hemophilia A or B with inhibitors.

Recombinant manufacturing minimizes the possibility of viral contamination

- NovoSeven® RT is the only recombinant bypassing agent for hemophilia with inhibitors
- Not made from human blood or plasma

NovoSeven® RT only has one main component

<table>
<thead>
<tr>
<th>NovoSeven® RT</th>
<th>FEIBA(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main component</td>
<td>Main components</td>
</tr>
<tr>
<td>- Recombinant activated factor VII</td>
<td>- Non-activated factor II</td>
</tr>
<tr>
<td></td>
<td>- Non-activated factor IX</td>
</tr>
<tr>
<td></td>
<td>- Non-activated factor X</td>
</tr>
<tr>
<td></td>
<td>- Activated factor VII</td>
</tr>
</tbody>
</table>

Important Safety Information

**What should I tell my healthcare provider before using NovoSeven® RT?**

- Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
  - congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
  - are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
  - history of heart or blood vessel diseases

Please see additional Important Safety Information throughout. Please see accompanying Prescribing Information.
Experience **fast bleed control** with NovoSeven® RT

**Fast to infuse**

When bleeds happen, stopping them quickly is important. The faster you infuse treatment, the sooner it can start working.

- NovoSeven® RT is given as an intravenous (IV) bolus injection\(^a\)
- NovoSeven® RT has **16x less infusion volume** than FEIBA\(^d\)

\(^a\)Administer as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.

**Important Safety Information**

What should I tell my healthcare provider before using NovoSeven® RT? (cont’d)

- Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

What are the possible side effects of NovoSeven® RT?

- The most common and serious side effects are blood clots
- Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

\(^d\)Individual doses for a joint bleed are compared and based on an 88 kg (194 lb) person.
NovoSeven® RT: Experience where it matters

Controlling bleeds, whenever they happen
• Proven to treat bleeds for people with hemophilia A or B with inhibitors

Safety supported by clinical experience
• 0.2% rate of blood clots reported in clinical trials

Speed when it’s needed
• Fast to mix, fast to infuse, and fast to control bleeds

NovoSeven® RT—committed to your experience
• More than 30 years of research and long-term clinical experience

Learn more at NovoSevenRT.com

Important Safety Information
What is the most important information I should know about NovoSeven® RT?
NovoSeven® RT may cause serious side effects, including:
• Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
• Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
• Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

Please see additional Important Safety Information throughout. Please see accompanying Prescribing Information.